PMID- 36704467
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230202
IS  - 2297-055X (Print)
IS  - 2297-055X (Electronic)
IS  - 2297-055X (Linking)
VI  - 9
DP  - 2022
TI  - Predicting the survival benefit of cardiac resynchronization therapy with 
      defibrillator function for non-ischemic heart failure-Role of the Goldenberg risk 
      score.
PG  - 1062094
LID - 10.3389/fcvm.2022.1062094 [doi]
LID - 1062094
AB  - AIMS: Primary prevention of sudden cardiac death (SCD) in non-ischemic heart 
      failure (HF) patients remains a topic of debate at cardiac resynchronization 
      therapy (CRT) implantation requiring individual risk assessment. Using the 
      Goldenberg SCD risk score, we aimed to predict, which non-ischemic HF patients 
      will benefit from the addition of an implantable cardioverter defibrillator (ICD) 
      to CRT at long-term. METHODS: Between 2000 and 2018 non-ischemic HF patients 
      undergoing CRT implantation were collected into our retrospective registry. The 
      Goldenberg risk score (GRS) was calculated by the presence of atrial 
      fibrillation, New York Heat Association (NYHA) class > 2, age > 70 years, blood 
      urea nitrogen > 26 mg/dl and QRS > 120 ms. The primary endpoint was all-cause 
      mortality, heart transplantation or left ventricular assist device implantation. 
      RESULTS: From 667 patients, 347 (52%) underwent cardiac resynchronization 
      therapy-pacemaker (CRT-P), 320 (48%) cardiac resynchronization 
      therapy-defibrillator (CRT-D) implantations. During the median follow up time of 
      4.3 years, 306 (46%) patients reached the primary endpoint (CRT-D 37% vs. CRT-P 
      63%; p < 0.001). CRT-D patients were younger (64 vs. 69 years; p < 0.001), 
      infrequently females (26 vs. 39%; p < 0.001), and had a lower ejection fraction 
      (27 vs. 29%; p < 0.01) compared to CRT-P patients. After GRS calculation, 
      patients were dichotomized by low (< 3) and high (>/= 3) scores. CRT-D patients 
      with low GRS showed a mortality benefit compared to CRT-P (HR 0.68; 95% CI 
      0.48-0.96; p = 0.03), high-risk patients did not (HR 0.84; 95% CI 0.62-1.13; p = 
      0.26). CONCLUSION: In our non-ischemic cohort, patients with low GRS showed a 
      clear long-term mortality benefit by adding ICD to CRT, however, in high-risk 
      patients no further benefit could be observed.
CI  - Copyright (c) 2023 Merkel, Schwertner, Behon, Kuthi, Veres, Osztheimer, Papp, 
      Molnar, Zima, Geller, Kosztin and Merkely.
FAU - Merkel, Eperke D
AU  - Merkel ED
AD  - Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
FAU - Schwertner, Walter R
AU  - Schwertner WR
AD  - Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
FAU - Behon, Anett
AU  - Behon A
AD  - Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
FAU - Kuthi, Luca
AU  - Kuthi L
AD  - Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
FAU - Veres, Boglarka
AU  - Veres B
AD  - Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
FAU - Osztheimer, Istvan
AU  - Osztheimer I
AD  - Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
FAU - Papp, Roland
AU  - Papp R
AD  - Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
FAU - Molnar, Levente
AU  - Molnar L
AD  - Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
FAU - Zima, Endre
AU  - Zima E
AD  - Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
FAU - Geller, Laszlo
AU  - Geller L
AD  - Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
FAU - Kosztin, Annamaria
AU  - Kosztin A
AD  - Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
FAU - Merkely, Bela
AU  - Merkely B
AD  - Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
LA  - eng
PT  - Journal Article
DEP - 20230110
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC9871919
OTO - NOTNLM
OT  - cardiac resynchronization therapy
OT  - implantable cardioverter defibrillator
OT  - non-ischemic heart failure
OT  - risk score
OT  - sudden cardiac death
COIS- AK receives consulting fees from Medtronic and Biotronik, and receives payment or 
      honoraria for lectures from Novartis, Bayer, Boehringer Ingelheim, Astra Zeneca, 
      Medtronic Biotronik, and Boston Scientific. BM receives grants or has contracts 
      with Abbott, Astra Zeneca, Argint International, Biotronik, Boehringer Ingelheim, 
      Boston Scientific, Bristol-Myers Squibb, CSL Behring, Daiichi Sankyo, Cerenis 
      Therapeutics SA DUKE Clinical Institut, Eli Lilly, Medtronic, Novartis, Terumo, 
      St. Jude, Zoll and VIFOR Pharma, and receives lecture fees from Abbott, Astra 
      Zeneca, Biotronik, Boehringer Ingelheim, and Novartis. LG receives lecture fees 
      from Biotronik, Medtronic, Johnson & Johnson Medical, and Abbott outside the 
      submitted work. EZ reports lecture and advisory fees from Biotronik, Medtronic, 
      Boston Scientific, and Zoll Medical, outside the submitted work. RP reports 
      lecture fees from Biotronik, Medtronic, and Abbott outside the submitted work. LM 
      reports lecture fees from Biotronik, Medtronic, and Abbott outside the submitted 
      work. The remaining authors declare that the research was conducted in the 
      absence of any commercial or financial relationships that could be construed as a 
      potential conflict of interest.
EDAT- 2023/01/28 06:00
MHDA- 2023/01/28 06:01
PMCR- 2022/01/01
CRDT- 2023/01/27 02:26
PHST- 2022/10/05 00:00 [received]
PHST- 2022/12/23 00:00 [accepted]
PHST- 2023/01/27 02:26 [entrez]
PHST- 2023/01/28 06:00 [pubmed]
PHST- 2023/01/28 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fcvm.2022.1062094 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2023 Jan 10;9:1062094. doi: 10.3389/fcvm.2022.1062094. 
      eCollection 2022.